Libros: para préstamos o consultas
Los siguientes libros han ingresado en la colección del SACT:
• Tietz textook of clinical chemistry and molecular diagnostics
Carl A. Burtis; Edward R. Ashwood; David E. Bruns, directores. – 4a ed. – St. Louis: Elsevier, 2006. – xxxi, 2412 p. – 28 x 22 cm. – ISBN 0-7216-0189-8.
Contenido: Laboratory principles – Analytical techniques and instrumentation – Principles of laboratory medicine – Analytes – Molecular diagnostics and genetics – Pathophysiology – Appendix.
• Cardiovascular biomarkers
David A. Marrow – Totowa, New Jersey. Editorial Human Press Inc. 2006 – xvii, 620p : il. col. : 26 x 18,5 cm.
Contiene: Biomarkers of myocardial necrosis: past, present, and future. – Analytical issue for the clinical use of cardiac troponin. – Definig myocardial infarction. – Biomarkers in the emergency department: rapid diagnosis and triage. – Cardiac troponin for risk assessment and management of non-ST-elevation acute coronary syndrome. – Biomarkers of necrosis for risk assessment and management of ST-elevation myocardial infarction. – Cardiac troponin after revascularization procedures. – Biomarkers of necrosis in heart failure: past present, and future directions. – Is there a role for cardiac troponin and other biomarkers in patients with pulmonary embolism?. – Cardiac troponin in conditions others than acute coronary syndromes. – Degradation of cardiac troponins: implications for clinical practice. – Developing a marker of ischemia: Clinical and research challenges. – Emerging biomarkers of myocardial ischemia. – Inflammation in cardiovascular disease: the biological basis of inflammatory biomarkers. – Analytic issues for the clinical use of C-reactive protein. – C-reactive protein as a tool for risk assessment in primary prevention. - High-sensitivity c-reactive protein for risk assessment in acute coronary syndromes. – Beyond c-reactive protein: novel markers of vascular inflammation. – Biomarkers of inflammation: implications in patients with heart failure. – Biomarkers of infection and risk of coronary heart disease. – Biology of the natriuretic peptides. – Analytic issues for the clinical use of B-type natriuretic peptide. – Clinical use of natriuretic peptides for the diagnosis and management of heart failure. – Natriuretic peptides in acute and chronic coronary artery disease. – Novel markers of hemodynamic stress. – Clinical and research applications of markers of thrombosis. – Measures of platelet activation and aggregation. – Monocyte-platelet aggregates in patient with ischemic heart disease. – Measurement of atherogenic lipoproteins in cardiovascular risk assessment. – Lipoprotein-associated phospholipase A2 and other lipid-realted biomarkers in cardiovascular disease. – A multimarker approach to evaluation of patients with acute coronat.
|
